RAPP

Rapport Therapeutics Inc. (RAPP)

Market Closed
12 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
30. 30
+1.52
+5.28%
$
1.04B Market Cap
- P/E Ratio
0% Div Yield
225,751 Volume
- Eps
$ 28.78
Previous Close
Day Range
28.03 30.5
Year Range
6.43 42.27
Want to track RAPP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 87 days
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know

Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know

Does Rapport Therapeutics, Inc. (RAPP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 4 days ago
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?

Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?

The consensus price target hints at a 75% upside potential for Rapport Therapeutics, Inc. (RAPP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 2 weeks ago
Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet

Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc. (RAPP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 month ago
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Rapport Therapeutics, Inc. (NASDAQ:RAPP ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 11:20 AM EDT Company Participants Abraham Ceesay - CEO, President, Treasurer & Director Troy Ignelzi - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Hi, everyone, and thank you for joining us at our 2025 Fifth Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.

Seekingalpha | 2 months ago
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

Zacks | 3 months ago
Meloni and Trump: An Oval Office Meeting With Rapport and Banter

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

In their meeting, President Trump made clear that he had special regard for Prime Minister Giorgia Meloni of Italy. She said he had accepted an invitation to go to Rome.

Nytimes | 7 months ago